TL011, anti CD20, for the treatment of rheumatoid arthritis
RA-TL011-101
Phase 1 mab completed
Quick answer
TL011, anti CD20, for the treatment of rheumatoid arthritis for Rheumatoid Arthritis is a Phase 1 program (mab) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Rheumatoid Arthritis
- Phase
- Phase 1
- Modality
- mab
- Status
- completed